University of Vermont research leads to first-of-Its-kind mesothelioma clinical trial

A promising new therapy for mesothelioma and metastatic cancer, arising from laboratory investigations at the University of Vermont (UVM), in the United States, is about to enter a Phase I clinical trial and launched in England in late 2021.

Dr Brian Cunniff, a faculty member in UVM’s Larner College of Medicine’s Pathology and Laboratory Medicine Department, identified the new therapeutic approach as a PhD student in partnership with his advisor, Emeriti Professor Dr. Nicholas Heintz, and UVM Alumni Dr. Kheng (Newick) Bekdache.

The approach targeted a universal vulnerability in cancer cells that could be exploited therapeutically. “All tumor cells are very reliant on efficient waste management systems to grow and survive; we were interfering with that,” said Dr Cunniff.

The pharmaceutical company, RS Oncology offered funding for the research and over the last four-and-a-half years, Dr Cunniff and his research team, in collaboration with Wake Forest School of Medicine and RS Oncology, have been directly responsible for showing the anti-cancer activity of the treatment approach they identified and in developing/testing a suitable formulation for delivery to humans.

“The drug takes away the ability of cells to metabolize toxic byproducts, so they essentially choke on their own exhaust,” Dr Cunniff said.

This will be a ‘first in human’ trial to test the safety and activity of this novel approach in malignant mesothelioma patients and will be subsequently considered as a targeted therapy for other cancers as well.

Introducing the new Health Companion portal

Working in collaboration with DaSH-Global, a real-world research company specialising in healthcare, we have developed a new digital patient app known as the ‘Health Companion’. The new system will allow patients to submit data regarding their quality of life and...

Join our Asbestos Commercial Club

If you are a business involved in the management of asbestos or the diseases it causes, why not join our Asbestos Commercial Club (MUKACC) to support the vital work that we do? Joining MUKACC can be a great morale booster for your staff, encouraging them to get...

CEO Liz Darlison to speak at the European Asbestos Conference

Mesothelioma UK’s CEO, Liz Darlison, has been confirmed as a speaker at the European Asbestos Forum Conference (EAF). The event will take place from 10-11 November in Amsterdam, in the Netherlands, where she will deliver a talk entitled, Establishing a National...